We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App





AI Helps Find Alternative Pharmaceutical Building Blocks for 12 Drugs under Investigation to Treat COVID-19

By HospiMedica International staff writers
Posted on 10 Aug 2020
Print article
Illustration
Illustration
A team of medicinal chemists at the University of Michigan (Ann Arbor, MI, USA) have used artificial intelligence (AI) to find alternative pharmaceutical building blocks for 12 drugs under investigation to treat COVID-19.

Amidst hopes that there will soon be a safe vaccine for COVID-19 as well as drugs to treat the disease, researchers fear that supply chain issues could result in a severe shortage of the fine chemicals needed to synthesize COVID-19 therapeutics and vaccines. The U-M team of medicinal chemists was approached by chemical supplier MilliporeSigma to devise solutions to the supply issue. The team combed the federal clinical trials database for drugs currently being considered for treatment of COVID-19, and then used the AI software Synthia to determine new ways to piece the drugs together.

The medicinal chemists traced the synthetic sequences of 12 drugs currently under investigation for treating COVID-19. Those drugs include bromhexine, camostat, cobicistat, darunavir, favipiravir, galidesivir, nelfinavir, ritonavir, umifenovir, ribavirin, remdesivir and baricitinib. The U-M team used crowd-sourcing to survey the vast amount of published and patented synthetic routes to build the 12 drugs. Then, the researchers encoded these known routes into the AI software, and asked it to come up with new recipes. This approach allowed the researchers to navigate around the starting materials that are already in the supply chain of the medicinal target compounds. Each search typically returned multiple proposals, which the researchers then winnowed down according to the overall economics of the starting materials and the overall sequence.

“The route we have found for some of these potential therapeutics might be longer than what’s out there, but in most cases, such as umfenovir, we’re actually finding routes that are shorter and starting materials that are cheaper than what’s currently available,” said U-M researcher Tim Cernak, an assistant professor of medicinal chemistry and chemistry. “We found a way to make the therapeutic bromhexine in one-step, which we are pretty stoked on.”

Related Links:

University of Michigan


Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.